Rodrigo Nalio Ramos

Rodrigo Nalio Ramos

Research

Our group investigates the tumor microenvironment with a focus on the role of immune system cells such as macrophages and T lymphocytes. Using spatial transcriptome techniques, multiparametric cytometry and ex-vivo functional assays, our aim is to establish, from a space-time perspective, the geospatial location and phenotypic and molecular characteristics of these immune cells in different solid and hematological tumors. These projects rely on close collaboration with hematologists and pathologists and a multidisciplinary group of researchers and students involved in uncovering new therapeutic targets for the treatment of cancer. 

Keywords: Immuno-oncology; Macrophages; T lymphocytes; Spatial transcriptome; cell therapy

EDUCATION

Post-doctorate in Immuno-oncology by Cordeliers Research Center, Université Paris Descartes, Sorbonne Université, Paris - France

Post-doctorate in Immuno-oncology by the Center for Cancer Immunotherapy, Instituto Curie, Paris - France

Ph.D. by the Department of Immunology of the Institute of Biomedical Sciences of the University of São Paulo and by the Université de Lyon -1 Claude Bernard, Centre de Recherche en Cancerologie de Lyon - France

INVESTIGATION AREAS

Hematology

ADITIONAL INFORMATION

AWARDS AND HONORS

2022 - Award Académie des Sciences in Paris/France, Les Grandes Avancées Françaises en Biologie (collaborator)

2019 - International Society of Paediatric Oncology - Odile-Schweisguth

2019 - Young Researcher travel grant, Institut Curie, France

2019 - Honorable mention, Honorable mention - Thereza Kipnis Award, Brazilian Society of Immunology - XL Congress of the Brazilian Society of Immunology

2014 - Honorable Mention - PhD Student, XXXIX Congress of the Brazilian Society of Immunology

Selected Publications

Ramos RN, Rodriguez C, Hubert M, Ardin M, Treilleux I, Ries CH, Lavergne E, Chabaud S, Colombe A, Trédan O, Guedes HG, Laginha F, Richer W, Piaggio E, Barbuto JAM, Caux C, Ménétrier-Caux C, Bendriss-Vermare N. CD163+ tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes. Clin Transl Immunology. 2020 Feb 13;9(2):e1108. PMID: 32082570; PMCID: PMC7017151.
doi: 10.1002/cti2.1108

Leruste A, *Ramos RN, *Tosello J, Tauziède-Espariat A, Brohard S, Han ZY, Beccaria K, Andrianteranagna M, Caudana P, Nikolic J, Chauvin C, Niborski LL, Manriquez V, Richer W, Masliah-Planchon J, et al. Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors. Cancer Cell. 2019 Dec 9;36(6):597-612.e8. Epub 2019 Nov 7. PMID: 31708437. (*igual contribuição)
doi: 10.1016/j.ccell.2019.10.008

Bourdely P, Anselmi G, Vaivode K, Ramos RN, Missolo-Koussou Y, Hidalgo S, Tosselo J, Nuñez N, Richer W, Vincent-Salomon A, Saxena A, Wood K, Lladser A, Piaggio E, Helft J, Guermonprez P. Transcriptional and Functional Analysis of CD1c+ Human Dendritic Cells Identifies a CD163+ Subset Priming CD8+CD103+ T Cells. Immunity. 2020 Aug 18;53(2):335-352.e8. Epub 2020 Jun 30. PMID: 32610077; PMCID: PMC7445430.
doi: 10.1016/j.immuni.2020.06.002

Nader GPF, Agüera-Gonzalez S, Routet F, Gratia M, Maurin M, Cancila V, Cadart C, Palamidessi A, Ramos RN, San Roman M, Gentili M, Yamada A, Williart A, Lodillinsky C, Lagoutte E, Villard C, Viovy JL, Tripodo C, Galon J, Scita G, Manel N, Chavrier P, Piel M. Compromised nuclear envelope integrity drives TREX1-dependent DNA damage and tumor cell invasion. Cell. 2021 Sep 30;184(20):5230-5246.e22. Epub 2021 Sep 21. PMID: 34551315.
doi: 10.1016/j.cell.2021.08.035

Nalio Ramos R, Missolo-Koussou Y, Gerber-Ferder Y, Bromley CP, Bugatti M, Núñez NG, Tosello Boari J, Richer W, Menger L, Denizeau J, Sedlik C, Caudana P, Kotsias F, Niborski LL, Viel S, Bohec M, Lameiras S, Baulande S, Lesage L, Nicolas A, Meseure D, Vincent-Salomon A, Reyal F, Dutertre CA, Ginhoux F, Vimeux L, Donnadieu E, Buttard B, Galon J, Zelenay S, Vermi W, Guermonprez P, Piaggio E, Helft J. Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer. Cell. 2022 Mar 31;185(7):1189-1207.e25. Epub 2022 Mar 23. PMID: 35325594.
doi: 10.1016/j.cell.2022.02.021

More Content